Human Papillomavirus 16 E6 Antibodies in Individuals without Diagnosed Cancer: A Pooled Analysis
- 31 March 2015
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 24 (4) , 683-689
Abstract
Background: The increasing incidence of oropharyngeal cancer in many developed countries has been attributed to human papillomavirus type 16 (HPV16) infections. Recently, HPV16 E6 serology has been identified as a promising early marker for oropharyngeal cancer. Therefore, characterization of HPV16 E6 seropositivity among individuals without cancer is warranted. Methods: A total of 4,666 controls were pooled from several studies of cancer and HPV seropositivity, all tested within the same laboratory. HPV16 E6 seropositive controls were classified as having (i) moderate [mean fluorescent intensity (MFI) ≥ 484 and Results: Thirty-two (0.7%) HPV16 E6 seropositive controls were identified; 17 (0.4%) with moderate and 15 (0.3%) with high seroreactivity. High HPV16 E6 seroreactivity was associated with former smoking [odds ratio (OR), 5.5; 95% confidence interval (CI), 1.2–51.8], and seropositivity against HPV16 L1 (OR, 4.8; 95% CI, 1.3–15.4); E2 (OR, 7.7; 95% CI, 1.4–29.1); multiple HPV16 proteins (OR, 25.3; 95% CI, 2.6–119.6 for three HPV16 proteins beside E6) and HPV33 E6 (OR, 17.7; 95% CI, 1.9–81.8). No associations were observed with moderate HPV16 E6 seroreactivity. Conclusions: High HPV16 E6 seroreactivity is rare among individuals without diagnosed cancer and was not explained by demographic factors. Impact: Some HPV16 E6 seropositive individuals without diagnosed HPV-driven cancer, especially those with seropositivity against other HPV16 proteins, may harbor a biologically relevant HPV16 infection. Cancer Epidemiol Biomarkers Prev; 24(4); 683–9. ©2015 AACR.Keywords
All Related Versions
This publication has 33 references indexed in Scilit:
- Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal CancersJournal of Clinical Oncology, 2013
- Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck CancerJournal of Clinical Oncology, 2013
- Human Papillomavirus Infections and Upper Aero-Digestive Tract Cancers: The ARCAGE StudyJNCI: Journal of the National Cancer Institute, 2013
- Human Papillomavirus and Diseases of the Upper Airway: Head and Neck Cancer and Respiratory PapillomatosisVaccine, 2012
- InterSCOPE Study: Associations Between Esophageal Squamous Cell Carcinoma and Human Papillomavirus Serological MarkersJNCI: Journal of the National Cancer Institute, 2012
- Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United StatesJournal of Clinical Oncology, 2011
- HPV-associated Oropharyngeal Cancers—Are They Preventable?Cancer Prevention Research, 2011
- Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancersBritish Journal of Cancer, 2011
- Trends in head and neck cancer incidence in Denmark, 1978–2007: Focus on human papillomavirus associated sitesInternational Journal of Cancer, 2010
- Human papillomavirus 16 and head and neck squamous cell carcinomaInternational Journal of Cancer, 2007